OATP2B1 缺陷改善了因虹素诱导的胃肠道毒性
Hanieh Taheri1, Peter de Bruijn2, Yang Li1
1Division of Pharmaceutics and Pharmacology, College of Pharmacy, the Ohio State University, Columbus, Ohio, USA.
Clinical and translational science
|December 30, 2025
概括
有机阴离子运输多OATP2B1调解了SN-38的肠道吸收,SN-38是虹色素的代谢物 (CPT-11). 缺少OATP2B1会减少CPT-11的胃肠道毒性,这表明OATP2B1的抑制是一种治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 氨酸 (CPT-11) 是转移性结直肠癌的重要化疗.
- 严重的胃肠道毒性限制了CPT-11的临床使用,其机制尚未完全理解.
- 在肠道细胞中的SN-38积累与CPT-11毒性有关.
研究的目的:
- 调查有机离子运输多2B1 (OATP2B1) 在SN-38肠道吸收中的作用.
- 确定OATP2B1是否是CPT-11引起的胃肠道毒性的一个关键因素.
主要方法:
- 使用了一种患有Oatp2b1缺乏症的小鼠模型.
- 向野生型和Oatp2b1缺乏的小鼠施用了CPT-11.
- 通过腹发病率,肠道长度变化和组织学检查评估胃肠道毒性.
主要成果:
- 与野生型小鼠相比,Oatp2b1缺乏的小鼠在CPT-11治疗后表现出明显较轻的腹和减少的肠道损伤.
- 组织学分析证实Oatp2b1缺陷小鼠的肠肠细胞损伤不严重.
- 这些保护作用发生在系统SN-38或其葡萄糖化物代谢物水平没有显著变化的情况下.
结论:
- OATP2B1是SN-38的肠道吸收载体.
- OATP2B1在调解CPT-11引起的胃肠道毒性方面发挥着关键作用.
- 血SN-38水平不是CPT-11毒性的可靠预测指标;OATP2B1抑制剂可以减轻副作用.
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
594
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
594
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
546
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
546
Drugs for Treatment of Diarrhea-Predominant IBS
593
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
593
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
400
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
400
Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
Carrier-Mediated Transport
975
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
975


